AbbVie Takes Charge of Potential IPF Therapies From Morphic Therapeutic

AbbVie Takes Charge of Potential IPF Therapies From Morphic Therapeutic
3.3
(8)

AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, exercising a licensing option under an earlier research partnership between the companies.

Integrins control a wide variety of cellular processes, including cell survival, cell migration, cell cycle progression, and immune system activation. Aberrant integrin signaling contributes to several diseases, including fibrotic diseases.

The protein αvβ6 integrin, in particular, has many functions. It is best known for activating another protein, called transforming growth factor-beta1 (TGF-β1), which is a well-established driver of fibrosis (scarring) in the lungs and elsewhere in the body. As such, it is believed that blocking αvβ6 integrin could lower the activity of TGF-beta1 to reduce fibrosis.

Multiple investigational αvβ6 integrin inhibitors — including the compounds MORF-720 and MORF-627 — have been developed by Morphic through the company’s MInT (Morphic Integrin Technology) platform. This platform is said to combine knowledge of structural biology with that of protein dynamics to discover compounds that might block integrins.

According to a press release from Morphic, an “extensive preclinical data package” supports its integrin inhibitors as potential oral IPF treatments.

“The preclinical data strongly support Morphic’s selective small molecule inhibitors of αvβ6 for development in fibrotic disease,” Praveen Tipirneni, MD, president and CEO of Morphic Therapeutic, said in the release.

AbbVie and Morphic entered into a research and development collaboration in 2018 aimed at advancing Morphic’s investigational integrin therapies for fibrosis-related conditions. This agreement gave AbbVie the exclusive right to license therapies being developed by Morphic. AbbVie has now exercised these rights for the αvβ6 integrin inhibitors.

In accordance with the earlier agreement, Morphic will receive a license fee of $20 million from AbbVie, in addition to the $100 million it received under the 2018 agreement. The company also has the potential to receive additional payments from AbbVie if candidate therapies are approved by regulatory agencies and commercialized.

“AbbVie has been an excellent partner through the preclinical development of this program and we believe that their decision to assume leadership for the next stages of development is a strong vote of confidence in our collaboration, as well as Morphic’s MInT platform to generate orally available integrin inhibitors,” Tipirneni said.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 110
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • new therapies
  • OATD-01 partnership
  • RareLaunch virtual workshops

How useful was this post?

Click on a star to rate it!

Average rating 3.3 / 5. Vote count: 8

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?